BioMarin Pharmaceutical (BMRN) Hits New All-Time High
Tweet
Share
E-mailGet Alerts BMRN Hot Sheet
Join SI Premium – FREE
Today, shares of BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) have hit a new 52-week high when the stock price went as high as $37.80. BioMarin stock has seen continued upside pressure since it announced that the FDA would approve its attempt to re-acquire the rights to its Kuvan product. Shares are up almost a dollar, or about 2.5%, today, extending yesterday's 3.5% gain.
Shares of BioMarin are up about 33% since the FDA approval announcement. On December 14, when the Kuvan announcement was released, analysts at Robert W. Baird and Soleil Securities Group raised their price targets on BioMarin to $40 and $57, respectively.
BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions.
Shares of BioMarin are up about 33% since the FDA approval announcement. On December 14, when the Kuvan announcement was released, analysts at Robert W. Baird and Soleil Securities Group raised their price targets on BioMarin to $40 and $57, respectively.
BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions.
You May Also Be Interested In
- Piper Sandler on BioMarin Pharmaceutical Inc. (BMRN): 'We Remain Bullish After Hosting Management Meetings'
- Benchmark explains why you should own this semiconductor stock
- Marvell earnings preview: Is a beat-and-raise quarter possible?
Create E-mail Alert Related Categories
Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
